Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant for Acute HAE Attacks in Japanese Patients
NCT03888755Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoint: Time to Onset of Symptom Relief. Started Mar 2015; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03888755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888755.